Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States
Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States
Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States
Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
St. Peter's Hospital, Helena, Montana, United States
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Cancer and Leukemia Group B, Chicago, Illinois, United States
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
Texas Oncology P.A., Dallas, Texas, United States
Greater Baltimore Medical Center, Baltimore, Maryland, United States
MD Anderson Cancer Center, Houston, Texas, United States
Arizona Clinical Research Center, Tucson, Arizona, United States
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Mercy Hospital and Medical Center, Chicago, Illinois, United States
Swedish Covenant Hospital, Chicago, Illinois, United States
Fox Chase Virtua Health Cancer Program at Virtua West Jersey, Voorhees, New Jersey, United States
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.